Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCY-1
2023-506216-40-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing Letermovir + valganciclovir with Valganciclovir + placebo (2 arms). Primary endpoint: Virological response at Week 3. Planned start Nov 2023; status: authorised.
02
Drugs
letermovirvalganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2023-506216-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506216-40-00.